KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Keros Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$11.06+0.40 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $218.99M
- P/E (TTM)
- –
- Dividend yield
- –
Keros Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Market Cap | $219.29M | $164.85M |
| Enterprise Value | -$38.32M | $87.06M |
| PS Ratio | 15.09 | 3.60 |
| PB Ratio | 0.84 | 2.03 |
| P/TBV Ratio | 0.84 | 2.31 |
Enterprise value
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| EV / Sales | -2.64 | 2.43 |
Income (trailing twelve months)
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Revenue | $14.54M | $57.94M |
| Operating Income | -$101.47M | -$21.44M |
| Pretax Income | -$86.10M | -$14.45M |
| Net Income | -$83.16M | -$22.46M |
| EBITDA | -$101.47M | -$16.91M |
| EPS (Diluted) | -$3.68 | -$0.83 |
Margins
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -698.0% | -44.5% |
| Pretax Margin | -592.3% | -13.0% |
| Profit Margin | -572.1% | -39.2% |
| EBITDA Margin | -698.0% | -31.3% |
| FCF Margin | -333.6% | -8.85% |
Returns
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -17.2% | -53.1% |
| Return on Assets (ROA) | -15.9% | -41.0% |
| Return on Invested Capital (ROIC) | -755.0% | -32.0% |
| Return on Capital Employed (ROCE) | -36.8% | -37.8% |
Growth
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -93.7% | 6.01% |
| Net Income Growth (YoY) | -543.0% | -37.7% |
| EPS Growth (YoY) | -1287.1% | -29.2% |
| FCF Growth (YoY) | -191.3% | 2.34% |
Balance sheet
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $257.61M | $62.42M |
| Net Cash (Debt) | $257.61M | $15.68M |
| Net Cash Per Share | $12.99 | $0.66 |
| Equity (Book Value) | $262.32M | $48.79M |
| Book Value Per Share | $13.23 | $1.36 |
| Tangible Book Value | $262.32M | $23.06M |
| Working Capital | $254.73M | $75.77M |
Financial position
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 21.96 | 3.30 |
| Quick Ratio | 21.20 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$47.99M | -$12.35M |
| Capital Expenditures | -$494.00K | -$1.06M |
| Free Cash Flow | -$48.49M | -$20.28M |
| FCF Per Share | -$2.45 | -$0.42 |
Efficiency
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.03 | 0.38 |
| Revenue Per Employee | $186.36K | $398.96K |
| Profits Per Employee | -$1.07M | -$703.34K |
| Employee Count | 78 | 74 |
Dividends and yields
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -37.9% | -22.7% |
| FCF Yield | -22.1% | -9.07% |
Shares
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 19,827,200 | 58,179,650 |
| Shares Change (YoY) | -32.4% | 11.1% |
| Shares Change (QoQ) | 0.48% | 0.54% |
| Float | 9,262,480 | 49,173,100 |
| Shares Held by Insiders | 53.3% | 11.6% |
| Shares Held by Institutions | 100.7% | 59.4% |
Taxes
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$2.94M | $91.50K |
Scores
| Measure | Keros Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 2.55 | -0.24 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Keros Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.